Lv4
630 积分 2025-10-16 加入
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2个月前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
4个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
5个月前
已完结
Abstract CT113: A dose-exploring, randomized, open-label, Phase I study for toripalimab subcutaneous injection in patients with advanced nasopharyngeal carcinoma
6个月前
已关闭
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
7个月前
已完结
The evolving landscape of tissue‐agnostic therapies in precision oncology
7个月前
已完结
Current status of therapy for advanced gastric carcinoma
8个月前
已关闭
Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium
8个月前
已完结
Primary gastric tumors of infancy and childhood: 54-year experience at a single institution
8个月前
已完结
Gastric cancer
8个月前
已完结
皖公网安备34019202002308
